Original Article
Somatic mutational analysis of *MED12* exon 2 in uterine leiomyomas of Iranian women

Shirin Shahbazi¹, Neda Fatahi², Soheila Amini-Moghaddam³

¹Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; ²Department of Molecular Medicine, Pasteur Institute of Iran, Tehran, Iran; ³Department of Obstetrics and Gynecology, Iran university of Medical Sciences, Tehran, Iran

Received May 12, 2015; Accepted June 24, 2015; Epub July 15, 2015; Published August 1, 2015

Abstract: Uterine leiomyomas are steroid-hormone dependent tumors of myometrial smooth muscle cells that affect numerous women throughout the world. Based on previous studies, we evaluated the mutations of *MED12* gene which encodes a co-activator protein involved in transcription regulation of the vast majority of RNA polymerase II-dependent genes. Exon 2 of *MED12* gene was genotyped by PCR-sequencing method. To determine the proportion of mutation-containing transcripts, RNA was extracted from the tissue samples and the corresponding amplified cDNA was sequenced. We observed 11 mutation positive lesions, 7 of them were located in codon 44. The c.131G>A was found to be the most common somatic mutation in this study. Our investigation also demonstrated two unreported mutations, one large deletion and one insertion. cDNA analyzing revealed that the mutated transcripts were predominantly expressed in almost all changes including the new insertion mutation c.122-123ins15. Our study provides further evidence that the *MED12* somatic mutations occur in a heterozygous manner and are mostly missense mutations in codon 44. The results displayed 47.8% mutation positive lesions in Iranian patients confirming the diversity between the populations.

Keywords: Uterine leiomyomas, MED12, somatic mutation

Introduction

Uterine leiomyomas are myometrial benign tumors that affect women of reproductive age. They originate from uterine smooth muscle tissue and are estrogen and progesterone dependent which explains their relapse at menopause [1].

The main clinical symptoms of the disease is excessive uterine bleeding, although; symptoms depend on the location of the myoma and its size [2]. The tumors appear earlier in black than in white women and are significantly larger with more severe symptoms [3, 4]. This would imply a genetic mechanism of inheritance that is supported by the results of twin's, family and multiple hereditary leiomyoma studies [4].

Using exome sequencing, Mäkinen et al. reported that 70% of the studied uterine leiomyomas have a range of somatic mutations in exon 2 of the mediator complex subunit 12 (MED12) gene [5]. The Mediator complex is a multi-subunit protein that regulates transcription by bridging between DNA regulatory elements and RNA polymerase II initiation complex [6]. Depending on the factors with which it interacts, MED12 operates as both transcriptional activator and repressor [7].

*MED12* gene is located on Xq13.1 and contains 45 exons. Germline mutations in *MED12* are responsible for at least two different forms of X-linked dominant mental retardation, Lujan-Fryns and Opitz-Kaveggia syndromes [8]. Previous studies suggest that leiomyoma-linked mutations in *MED12* are involved in the activation of Wnt pathway leading to an impaired regulation of cell growth and tumorigenesis [9, 10]. Recently it has been reported that somatic *MED12* gene mutations lead to the highly specific reduction in CDK activity as a result of impaired MED12/Cyclin C-CDK8/19 interaction [11].
**MED12 mutation in uterine leiomyomas**

**MED12** leiomyoma-linked mutations mostly occur at the nucleotides 130 and 131 of the exon 2, changing a conserved glycine amino acid located at position 44. However the distribution of the mutations is different based on the ethnic groups [12]. To further investigate the frequency of mutation-positive leiomyoma in Iranian women we conducted a somatic mutation detection study to verify if it is comparable to those reached by other studies.

**Material and methods**

**Subjects and tissue sample collection**

Twenty three patients were randomly selected from the women referred to the genecology department at Firoozgar general hospital (Tehran, Iran) from June 2013 to March 2014. All the patients were new cases with no medical history of surgery or therapy regarding gynecologic problems. They were first visited by an expert gynecologist and subjected to imaging and laboratory tests according to the standard diagnostic approaches. Each patient contributed to the study signed a written informed consent approved by the ethics committee of Iran university of Medical Sciences. Leiomyoma tissue samples were obtained via surgical operations. In addition, normal matched myometrium tissue was obtained from each patient. Every tissue sample was sectioned into two replicates; one replicate was examined by a pathologist for the evaluation of histopathological features. The other replicate was immediately transferred into liquid nitrogen containers and stored until molecular analysis.

**DNA extraction and mutation detection**

Genomic DNA was extracted from 50 mg of leiomyoma or normal myometrial tissue using DNA Isolation Kit for Cells and Tissues (Roche). Extraction of the peripheral blood genomic DNA was also performed using QIAamp mini kit (Qiagen) and considered as the control genomic DNA. The concentration and purity of the isolated DNA was determined by spectrophotometry (Nanophotometer™, Implen, Germany). High quality DNA samples (A260/280≥1.8, A260/A230>1.8) were selected and kept at -80°C until used for cDNA synthesis. Up to 1 µg RNA was converted to cDNA using Quantitect® reverse transcription kit (Qiagen) according to the manufacturer’s instruction. To verify the integrity of the cDNA, the RT-PCR experiment was performed by GAPDH specific primers. Using the specific primers [5] the cDNA of MED12 exon 2 was amplified and undergone sequencing to determine the proportion of mutation-containing transcript.

**RNA extraction and RT-PCR**

Tissue samples (100 mg) were treated with TRI Reagent® (SIGMA-Aldrich) as recommended by the manufacturer and RNA was extracted using RNeasy mini kit (Qiagen). The RNA concentration and purity were determined by spectrophotometry. High quality RNAs (A260/280≥1.8, A260/A230>1.8) were selected and kept at -80°C until used for cDNA synthesis. A high-quality DNA sample (A260/280≥1.8) was used as a template for the amplification of MED12 exon 2 using specific primers [5]. The amplified fragments were sequenced on ABI 3130 Genetic Analyzer instrument. The sequencing data were verified using ChromasPro software and aligned on the BLAST website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). All sequence changes were confirmed on both strands.

**Statistics**

Data were analysis by SPSS software (V.18). The differences in genotypes were assessed by standard Chi-squared analysis, with corresponding 95% confidence intervals (CI). p value <0.05 was considered statistically significant.

**Results**

**Clinical characteristics**

The mean age of the patients was 45.5±8.05 years old. The distribution of the gravidity and parity were 2.47±1.63 and 2.19±1.47 respectively. The data also revealed that the most common chief complaints of the patients were abnormal uterine bleeding (61.9%) and abdominal pain (32.3%). The main leiomyoma subtype allocated to the intramural with 61.5% of the samples followed by 23.1% of subserous tumors. The tumor size was <30 mm in 33.4%, 30-50 mm in 22.2% and >50 in 44.4% of the cases.

**Tissue samples DNA genotyping**

To search for MED12 mutations associated with leiomyoma, we checked the tissue genom-
MED12 mutation in uterine leiomyomas

Table 1. Summary of the observed MED12 exon 2 mutations and patients' characteristics

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age at diagnosis</th>
<th>Type of fibroids</th>
<th>Size</th>
<th>Nucleotide change</th>
<th>Predicted protein change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>Intramural</td>
<td>Multiple</td>
<td>Large deletion</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>46</td>
<td>Subserous</td>
<td>Multiple, the biggest one 10-30 mm</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
<tr>
<td>10</td>
<td>30</td>
<td>Subserous</td>
<td>Multiple, the biggest one 10-30 mm</td>
<td>c.130G&gt;T</td>
<td>p.G44C</td>
</tr>
<tr>
<td>12</td>
<td>45</td>
<td>Intramural</td>
<td>Multiple, the biggest one 30-50 mm</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
<tr>
<td>13</td>
<td>36</td>
<td>Intramural</td>
<td>&gt;50 mm</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
<tr>
<td>15</td>
<td>40</td>
<td>Intramural</td>
<td>Multiple</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
<tr>
<td>16</td>
<td>42</td>
<td>Intramural/Subserous</td>
<td>Multiple</td>
<td>c.107T&gt;G</td>
<td>p.L36R</td>
</tr>
<tr>
<td>17</td>
<td>36</td>
<td>Subserous</td>
<td>Multiple, the biggest one 10-30 mm</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
<tr>
<td>20</td>
<td>50</td>
<td>Submucous</td>
<td>10-30 mm</td>
<td>c.122-123Ins15</td>
<td>p.V41_K42Ins15</td>
</tr>
<tr>
<td>21</td>
<td>48</td>
<td>Intramural</td>
<td>&lt;30 mm</td>
<td>c.130G&gt;A</td>
<td>p.G44S</td>
</tr>
<tr>
<td>23</td>
<td>37</td>
<td>Intramural/Subserous</td>
<td>Multiple, the biggest one &gt;50 mm</td>
<td>c.131G&gt;A</td>
<td>p.G44D</td>
</tr>
</tbody>
</table>

A large deletion was first revealed by gel electrophoresis (Figure 1). Sequencing results showed a 91bp deletion starting from 56bp upstream of the splice acceptor site of exon 2. To the best of our knowledge, this is the largest deletion of MED12 ever detected in uterine leiomyoma. Additionally, in our study, one novel insertion mutation c.122-123ins15 was identified (Figure 2A, 2B). In the rest of the tissue samples (52.2%), we didn’t observed any mutation in exon 2. For all the lesions with MED12 mutations, normal matched myometrium tissues were examined. None of the samples showed the corresponding variations, confirming the somatic nature of the MED12 mutations.

To evaluate the association between MED12 mutation status and clinical characteristics, standard Chi-square analysis was conducted. We examined the age at diagnosis, gravidity, parity, miscarriages, menopausal condition, smoking, type of fibroids, and the size of...
MED12 mutation in uterine leiomyomas

Figure 2. Sequencing of insertion mutation c.122-123ins15 (A), Forward DNA sequencing. (B) Reverse DNA sequencing. (C) Forward cDNA sequencing.

Figure 3. The chromatogram of IVS1-8T>A mutation. Top, leiomyoma genomic DNA sequencing. Down, leiomyoma cDNA sequencing.
MED12 mutation in uterine leiomyomas

Tumors. No significant correlation was found between these confounding factors and MED12 genotype, indicating that MED12 somatic DNA variants occur independently.

**Verification of allele-specific mRNA expression in tissue samples**

To prove whether the MED12 mutant alleles are expressed in the tumors, RNA was extracted from each sample carrying MED12 DNA variants. cDNA analyzing of these samples revealed that the mutant alleles were mainly present in the cDNA sequence. As indicated in Table 1, we found splice site mutation IVS1-8T>A in one sample. This mutation was previously reported by Mäkinen et al. [5]. They predicted and confirmed addition of six bases to the transcript by cDNA sequencing. Although we observed this additional six bases in cDNA, the dominant transcript was coded by the wild type allele (Figure 3).

Regarding the new insertion mutation found in our study, the cDNA sequencing revealed that the transcripts carrying c.122-123ins15 are dominantly expressed (Figure 2C).

**Discussion**

To investigate the genetic basis of uterine leiomyomas in Iranian patients, we examined tumor-derived tissues from 23 unrelated patients. By PCR-sequencing method, we found 11 samples representing mutations with 7 different alterations in the exon 2 of MED12 gene. This study provides further evidence that the mutations occur in a heterozygous manner and are mostly missense mutations in codon 44. As reported by the previous studies, c.131G>A was highly occurred [5, 13, 14]. Besides confirming the results of earlier investigations, our study also demonstrates two unreported mutations, one large deletion and one insertion. In transcript analysis, the sequenced cDNAs showed that mutated transcript was predominantly expressed compared to the wild-type in nearly all mutations including the novel insertion mutation, c.122-123ins15. As an exception, following the splice site mutation IVS1-8T>A, the aberrant transcript was almost not expressed. Although normal tissue contamination couldn’t be ignored.

In our study the incidence of MED12 mutation was found to be 47.8%. As it was mentioned before, the first report of MED12 somatic changes in leiomyomas of Finnish patients identified that 70% of samples bore mutations [5]. They recently replicated this report by the observation of mutations in 83.0% of the sporadic uterine leiomyomas from the consecutive patient series and 85.5% in unselected sporadic cases [15]. A Japanese series displayed the same incidence of mutation-positive conventional leiomyomas. They found MED12 mutations in 36 out of 45 (80%) samples [14]. A French study showed an incidence of 66.6% in typical leiomyomas. They also observed MED12 protein expression in all classical types comparing to 40% of atypical tumors and further conclude that MED12 expression could be inhibited in malignant tumors [16]. By Sanger sequencing in 143 samples of North American women, 100 (67%) genotyped leiomyomas were found to be mutated [17].

Besides these reports of high mutation incidence, several other studies showed a rate of about 50% in different ethnic groups. In a set of 28 uterine leiomyomas from black African or coloured South African patients 14 (50%) mutation positive tumors were detected [13]. Prior published results of Korean patients showed 52.2% mutation-positive lesions [18]. Using uterine leiomyomas as a control group of malignant smooth muscle tumors, Markowski and colleagues detected MED12 mutations in 10/21 (47.6%) of European samples [19]. A recent American study detected aberrant genotypes in 54% (15/28) of classical uterine leiomyomas [20].

As previously described by other researchers, the incidence of MED12 mutations shows ethnic differences. Our results displayed fewer mutation positive lesions than formerly published data confirming the diversity between the populations. Further studies are necessary in order to conclude whether these differences are consistent across different settings and are clinically meaningful.

**Acknowledgements**

The authors acknowledge the contribution of the subjects in this study.

**Disclosure of conflict of interest**

None.
References


